Join
Live feed
·
PRReleasevia Quantisnow
Prime Medicine Inc. logo

Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency

ByQuantisnow·Wall Street's wire, on your screen.
PRME· Prime Medicine Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PRME (Prime Medicine Inc.) and more on Quantisnow.